Difference Between Type 1 and Type 2 Myocardial Infarction
Type 1 MI is caused by acute coronary atherothrombosis from plaque rupture or erosion with thrombus formation, while Type 2 MI results from oxygen supply-demand mismatch unrelated to acute coronary atherothrombosis. 1, 2
Pathophysiologic Mechanisms
Type 1 MI
- Primary mechanism: Atherosclerotic plaque disruption (rupture, ulceration, fissure, erosion, or dissection) with resulting intraluminal thrombus in coronary arteries 3
- Leads to decreased myocardial blood flow and/or distal platelet emboli causing myocyte necrosis
- May have underlying severe CAD, though 5-20% have non-obstructive or no CAD on angiography 4
Type 2 MI
- Primary mechanism: Imbalance between myocardial oxygen supply and demand where a condition other than coronary plaque instability is the culprit 3
- Common precipitants include:
Clinical Characteristics
Patient Demographics
Type 2 MI patients are typically older (mean age 79 vs 75 years), have more non-cardiovascular comorbidities, and paradoxically have less prevalent traditional atherosclerotic risk factors compared to Type 1 MI 6, 5. Women are more prevalent in Type 2 MI presentations (53% vs 34%) 7.
Diagnostic Criteria
Both types require:
- Elevated cardiac troponin (rise and/or fall with ≥1 value above 99th percentile)
- PLUS evidence of myocardial ischemia (symptoms, ECG changes, new Q waves, imaging evidence of wall motion abnormality, or coronary thrombus) 3
Key Distinguishing Features
Biomarker Patterns
Type 1 MI demonstrates significantly higher troponin elevations relative to inflammatory markers:
- Higher hs-cTnI peak/upper limit of normal ratio (559 vs 286) 7
- Higher hs-cTnI peak/CRP ratio (114 vs 83) 7
- Higher hs-cTnI peak/procalcitonin ratio (12,592 vs 4,609) - this is the strongest predictor 7
- Higher hs-cTnI peak/NTproBNP ratio (0.7 vs 0.3) 7
Coronary Anatomy
Type 1 MI shows greater atherosclerotic plaque burden on CT coronary angiography:
- Greater total plaque burden (44% vs 35%)
- Greater noncalcified plaque burden (39% vs 34%)
- Significantly greater low-attenuation plaque burden (4.15% vs 1.64%) - the strongest discriminator 8
- Low-attenuation plaque is an independent predictor of Type 1 MI (adjusted OR 3.44) 8
Management Implications
Type 1 MI
Requires immediate reperfusion-focused therapy:
- Dual antiplatelet therapy (aspirin + P2Y12 inhibitor)
- Early invasive coronary angiography with revascularization
- Intensive statin therapy
- Standard post-MI secondary prevention 9, 1
Type 2 MI
Focus on treating the precipitating cause of supply-demand mismatch:
- Address underlying trigger (sepsis, anemia, arrhythmia, hypoxia, hypotension)
- Coronary angiography is NOT routinely indicated but consider when:
- Diagnostic uncertainty between Type 1 and Type 2
- Known or suspected significant CAD (present in ~67% of Type 2 MI patients) 6
- Medical therapy is substantially underutilized - Type 2 MI patients receive antiplatelet therapy (79% vs 96%), statins (61% vs 80%), and coronary angiography (11% vs 54%) far less frequently than Type 1 MI 5
- Despite lack of trial evidence, observational data suggest statins, β-blockers, and RAAS inhibitors may improve survival 10
Critical Clinical Pitfalls
The most important caveat: When diagnostic uncertainty exists between Type 1 and Type 2 MI, manage as presumed Type 1 MI until proven otherwise 6. The consequences of missing acute coronary atherothrombosis are far greater than temporarily treating supply-demand mismatch with antiplatelet therapy.
Type 2 MI carries worse prognosis with higher 1-year mortality (38.8% vs 26.6%), driven primarily by greater comorbidity burden and non-cardiovascular mortality 5. However, two-thirds have underlying CAD requiring secondary prevention strategies 6.
Antiplatelet therapy is contraindicated in Type 2 MI caused by severe hemorrhage and anemia 9.
The distinction requires integration of clinical context, troponin kinetics, ECG patterns, precipitating conditions, and often coronary imaging - no single biomarker provides definitive separation 11.